Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 6, 2026VaccinesOpen Access

Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYuying LiuFYFei YinWLWen-Juan Li

Discussion

Loading...

Member takes

Overview

Preclinical immunogenicity and efficacy of a novel HPV vaccine in mice and rats, indicating potential for clinical trials.

Key Points

  • To preclinically evaluate the immunogenicity and durability of a new recombinant 9-valent HPV vaccine.
  • Assessed molecular weight and purity via SDS-PAGE with Coomassie Brilliant Blue staining.
  • Characterized VLPs using cryo-electron microscopy and dynamic light scattering (DLS).
  • Evaluated the immunogenicity in BALB/c mice and Wistar rats with various dosing regimens.
  • Monitored antibody responses using ELISA and neutralization assays over 16-24 weeks.
  • VLPs appeared as uniformly distributed hollow particles approximately 45–65 nm in diameter.
  • The vaccine demonstrated robust immunogenicity comparable to Gardasil®9 in both animal models.
  • Induced long-lasting immune responses in both mice and rats.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69fa979b04f884e66b53186bhttps://doi.org/10.3390/vaccines14050407
View Full Paper
Ask AI
Bookmark
Share